Blenrep Den europeiske union - norsk - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - multippelt myelom - antineoplastiske midler - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Methotrexate Pfizer 2.5 mg Norge - norsk - Statens legemiddelverk

methotrexate pfizer 2.5 mg

pfizer as - metotreksat - tablett - 2.5 mg

Cinacalcet Aristo 30 mg Norge - norsk - Statens legemiddelverk

cinacalcet aristo 30 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg

Cinacalcet Aristo 60 mg Norge - norsk - Statens legemiddelverk

cinacalcet aristo 60 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg

Cinacalcet Aristo 90 mg Norge - norsk - Statens legemiddelverk

cinacalcet aristo 90 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg

Cinacalcet STADA 30 mg Norge - norsk - Statens legemiddelverk

cinacalcet stada 30 mg

stada arzneimittel ag - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg

Cinacalcet STADA 60 mg Norge - norsk - Statens legemiddelverk

cinacalcet stada 60 mg

stada arzneimittel ag - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg

Cinacalcet STADA 90 mg Norge - norsk - Statens legemiddelverk

cinacalcet stada 90 mg

stada arzneimittel ag - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg

Cozaar 12.5 mg Norge - norsk - Statens legemiddelverk

cozaar 12.5 mg

merck sharp & dohme b.v. - losartankalium - tablett, filmdrasjert - 12.5 mg

Hemangiol Den europeiske union - norsk - EMA (European Medicines Agency)

hemangiol

pierre fabre medicament - propranolol hydroklorid - hemangiom - betablokkende midler - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.